MedPath

Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea

Completed
Conditions
Migraine Disorders
Headache
Registration Number
NCT01976611
Lead Sponsor
Allergan
Brief Summary

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat Chronic Migraine in clinical practice.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
402
Inclusion Criteria
  • Patients treated with botulinum toxin Type A for chronic migraine in clinical practice.
Exclusion Criteria
  • None.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Participants with Adverse Events and Adverse Drug Reactions4 Years
Headache Impact Test-6 (HIT-6) Score Using a 5-Point Scale4 Years
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.